PIA
ESPR

Piedmont Investment Advisors’s Esperion Therapeutics ESPR Stock Holding History

Piedmont Investment Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-397
Closed -$16K – 1426
2018
Q2 		$16K Sell
397
-6,514
-94% -$329K ﹤0.01% 1652
2018
Q1 		$500K Buy
+6,911
New +$507K 0.01% 414

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Piedmont Investment Advisors's ESPR Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Esperion Therapeutics (ESPR) in Q3 2018, closing a stake of 397 shares — an estimated $16K sold.

Piedmont Investment Advisors first reported a position in ESPR in Q1 2018 and held it in 2 quarters. The position peaked at $500K in Q1 2018. 155 funds tracked by Wall St. Rank hold ESPR as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Esperion Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 397 Esperion Therapeutics shares in Q3 2018, an estimated $16K.
  • Piedmont Investment Advisors first reported a position in Esperion Therapeutics in Q1 2018 and held it in 2 quarters.
  • Piedmont Investment Advisors's Esperion Therapeutics position peaked at $500K in Q1 2018.
  • 155 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.